Patients with symptomatic CNS metastases or leptomeningeal involvement 
Patients with known brain metastases, unless these metastases have been treated and/or have been stable for at least six months prior to study start. Subjects with a history of brain metastases must have a head CT with contrast to document either response or progression. 
Patients with bone metastases as the only site(s) of measurable disease 
Patients with hepatic artery chemoembolization within the last 6 months (one month if there are other sites of measurable disease) 
Patients who have been previously treated with radioactive directed therapies 
Patients who have been previously treated with epothilone 
Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 
Patients with severe cardiac insufficiency patients taking Coumadin or other warfarin-containing agents with the exception of low dose warfarin (1 mg or less) for the maintenance of in-dwelling lines or ports 
Patients taking any experimental therapies history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ 
Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae 
Patients with a medical or psychiatric illness that would preclude study or informed consent and/or history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits 
HIV+ patients 
Pregnant or lactating females.       
    
